Sector Expert: Steve Brozak

WBB Securities

Image: Steve Brozak

Steve Brozak is the managing partner and president of WBB Securities, an investment bank and financial analytical firm engaged in the biotechnology, pharmaceutical and medical device sectors. Before cofounding WBB Securities, he worked for several Wall Street firms, including Salomon Brothers, Dean Witter, Cowen & Company, and Alex. Brown & Sons. As WBB Security's Senior Equity Analyst, Brozak has been acknowledged for his investment acumen and equity research performance by the major analyst ranking systems. In 2013, he was selected as the #2 ranked analyst in the pharmaceuticals sector by the StarMine/Financial Times Industry Analyst Awards system. The Wall Street Journal distinguished Brozak as its Best on the Street Medical Equipment and Supplies financial analyst in its 19th Annual Best on the Street Survey in 2011. In 2010, Brozak received StarMine Thompson Reuters/Financial Times Best Brokerage Analyst award for his selection of top-performing companies in the biotechnology space. With a 25-year track record in banking and analysis in the life sciences space, Brozak also works as media commentator on the life sciences sector on the web, on television, and in print media. Brozak served in the United States Marine Corps and now serves on the Secretary of the Navy's Navy and Marine Corps Retiree Council, where he focuses on healthcare, benefits and other veteran issues. He received a bachelor's degree and a master's degree in business administration from Columbia University, and also holds FINRA licenses 3, 7, 8, 24, 63, 65, 79, 86, 87 and 99.



Recent Quotes

"With OMER's product, surgeons will receive a better product from a single-source, FDA-regulated company."

The Life Sciences Report Interview with Steve Brozak (12/30/14)
more >

"The new year holds a great deal of promise for the field of regenerative medicine, with companies like NEO at the forefront."

The Life Sciences Report Interview with Steve Brozak (12/30/14)
more >

"OMER's Omidria is FDA-approved, proven sterile and safe, and reimbursable by payers."

The Life Sciences Report Interview with Steve Brozak (11/13/14)
more >

"NBS will announce results from its Phase 2b PreSERVE-AMI trial on Nov. 17."

The Life Sciences Report Interview with Steve Brozak (11/13/14)
more >

"I think it would be easy for OMER to single-handedly take the market."

The Life Sciences Report Interview with Steve Brozak (2/6/14)
more >

"NBS' initial trial data has been positive beyond expectations."

The Life Sciences Report Interview with Steve Brozak (2/6/14)
more >

"We believe ATHX is still undervalued."

The Life Sciences Report Interview with Steve Brozak (2/6/14)
more >

"There is exciting potential for CYTX's therapy."

The Life Sciences Report Interview with Steve Brozak (2/6/14)
more >



Due to permission requirements, not all quotes are shown.